Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge

 
• By Manas Mishra
  
The negotiations included Novo Nordisk's semaglutide, Merck's Janumet and AbbVie's Linzess. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Scrip